Literature DB >> 19915297

Secondary adrenal insufficiency and primary antiphospholipid syndrome.

Eman M Alfadhli1.   

Abstract

A woman with isolated ACTH deficiency and empty sella in a background of primary antiphospholipid syndrome (APS) is described. A 24-year-old woman was admitted for premature delivery at 30 weeks of gestation and was found to have severe pulmonary hypertension and right sided heart failure. A few hours after delivery, without excessive blood loss, she suddenly lost consciousness, and was found to be hypotensive and hypoglycemic. The findings on hormonal evaluation were consistent with isolated secondary adrenal insufficiency as both ACTH and cortisol levels were very low. Magnetic resonance imaging of the pituitary fossa showed an empty sella. Her severe cor pulmonale was found to be due to primary APS. The patient was given replacement of glucocorticoid and treated with frusemide, spironolactone, warfarin, sildenafil and inhaled iloprost for her pulmonary hypertension, after which her clinical status improved substantially. Follow-up tests of the hypothalamic-pituitary axis found normal serum LH, FSH, TSH, FT4 and prolactin secretion; serum ACTH and plasma cortisol levels remained low.

Entities:  

Mesh:

Year:  2009        PMID: 19915297     DOI: 10.2169/internalmedicine.48.2640

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  3 in total

1.  Gestational pulmonary arterial hypertension.

Authors:  Matthew Moll; Julie G Payne; Melissa H Tukey; Harrison W Farber
Journal:  Pulm Circ       Date:  2015-12       Impact factor: 3.017

2.  Autoimmune hypophysitis as a cause of adrenocorticotropic hormone deficiency in pulmonary arterial hypertension: a case report.

Authors:  Genki Ichihara; Masaharu Kataoka; Yoshinori Katsumata; Keiichi Fukuda
Journal:  Eur Heart J Case Rep       Date:  2021-03-31

3.  Adrenal failure and antiphospholipid syndrome.

Authors:  Katarina Mlekuš Kozamernik; Mojca Jensterle; Aleš Ambrožič; Marija Pfeifer
Journal:  J Int Med Res       Date:  2020-07       Impact factor: 1.671

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.